MedX Announces Proposed Extension of Non-Brokered Private Placement

Executive Summary

• MedX Health Corp. has announced an extension of up to 30 days for the closing of its previously announced non-brokered private placement, which is subject to TSX-V acceptance.
• The company is raising up to $2.5 million through the sale of units to accredited investors, with funds designated for the development of its SIAscopy® technology and the DermSecure® telemedicine platform.
• The placement involves the issuance of units comprising common shares and warrants, with specific terms for both investor warrants and agent commissions.

Key Details

• Transaction Structure: Non-brokered Private Placement of up to 33,333,333 Units at $0.075 per Unit.
• Gross Proceeds: Up to $2,500,000.
• Unit Composition: Each Unit consists of one (1) fully paid common share and one-half (1/2) of a Share Purchase Warrant.
• Investor Warrant Terms: Each whole Share Purchase Warrant is exercisable to purchase one (1) further Common Share at a price of $0.10. The exercise period is one year commencing on the date of issue.
• Closing Conditions: Closing is subject to a minimum subscription of $500,000, receipt of all relevant regulatory and Stock Exchange approvals/acceptances, and may take place in tranches.
• Use of Proceeds: Continuing development of the SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes.
• Agent Compensation: Qualified agents receive a cash commission of 8% of gross proceeds from subscriptions introduced by them.
• Agent Warrant Terms: Agents receive warrants equal to 8% of subscriptions introduced. Each Agent’s Warrant (non-transferable) entitles the holder to acquire a unit (one common share and one-half agent’s share purchase warrant) at a price of CAD$0.09. The agent’s share purchase warrant allows acquisition of one additional Common Share at CAD$0.10.
• Agent Warrant Expiry: Agent’s Warrants and resulting warrants expire one year following the date of issuance of the original Agent’s Warrant.
• Insider Participation: It is anticipated that certain Insiders may participate in the Placement.
• Previous Announcement: The placement was previously announced on July 25, 2025.